CClinicalTrials.gg
CompletedNCT05636033ALCOOLNETUpdated Apr 27, 2026

Semantic Networks in Alcohol Use Disorder Patients: Exploratory Study

An observational study in Alcohol Use Disorder, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
41
Ages
30 Years to 60 Years
Sex
All
01

Study summary

Alcohol Use Disorder (AUD) is a major public health problem, characterized by a high rate of relapse. Chronic and excessive alcohol consumption notably induces frontal brain alterations and cognitive impairments such as executive dysfunction and an attentional bias for alcohol, participating to the risk of relapse. In effect, AUD patients preferentially process alcohol-related cues, which could reflect a reorganization of the patients' semantic network. The investigators hypothesize that in AUD patients, semantic associations in memory are reorganized with a higher centrality of alcohol-related elements. To the investigators knowledge, no studies have explored semantic associations and/or semantic networks in AUD.

A study, conducted in patients with neurological damage, showed that frontal lesions are associated with excessive strength in semantic associations, and difficulties to generate remote associations. This excessive strength in semantic associations could reduce the ability to inhibit automatisms and to adapt to new context.

Objective: The objective of this study is to explore whether and how AUD patients have a different organization of semantic associations than healthy controls, and whether this reorganization influences the alcohol consumption over the months following the withdrawal. The investigators will also explore how it relates to neuropsychological assessment of flexibility, executive functions, and impulsivity. To these purposes, the investigators will use two original verbal tasks (Free Generation of Associates Task, FGAT and Associative Judgment Task, AJT) assessing word associations and allowing the estimation of semantic networks using graph theory, in combination with neuropsychological testing, in AUD patients and in healthy controls.

Methods: This study will include a group of 30 AUD patients and a group of 30 healthy controls. Both groups will be assessed twice, at baseline (T1; early in abstinence for AUD patients) and after a three-month period (T3). For the two groups, T1 and T3 assessments will include the two semantic association tasks (FGAT and AJT). For AUD patients, assessments will also involve neuropsychological testing of impulsivity, flexibility, and attentional bias. Besides, in AUD patients, data about alcohol consumptions will be collected six weeks (T2) and three months (T3) following the baseline assessment to classify patients as relapsers or abstainers.

02

Conditions studied

  • Alcohol Use Disorder

Browse trials for

Keywords

  • alcohol use disorder
  • semantic association
  • semantic networks
  • cognition
03

In context

Alcoholism

1,606 studies on the registry are indexed under Alcoholism; 329 are open to participants now.

This study's enrollment of 41 is below the median of 180 across 173 observational studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 375 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Two groups of participants will be included in this study. The first one consists of a pool of alcohol use disorder, the second one consists of a pool of healthy controls ; they will be matched as much as possible on age, gender, and educational level.

Inclusion criteria

For alcohol use disorder patients

  • Severe alcohol use disorder
  • French as mother tongue
  • Right-hander
  • Patient abstinent from alcohol since 15 to 30 days at the inclusion
  • Patient free from benzodiazepine since at least 48hours at the inclusion
  • Patient who gave his informed written consent
  • Currently in outpatient or inpatient care

For healthy controls

  • French as mother tongue
  • Right-hander
  • Participant who gave his informed written consent

Exclusion criteria

Exclusion Criteria:

For alcohol use disorder patients

  • Patient under guardianship or under justice safeguard measures
  • Patient under measure of therapeutic injunction
  • Pregnancy or breastfeeding declared
  • Meeting Diagnostic and Statistical Manual 5 (DSM) criteria for substance use disorder other than Tobacco
  • Meeting DSM-5 criteria for non substance use disorder
  • Patient presenting severe or progressive disease that interfere with experimental tasks, such as neurological diseases (TBI, epilepsy, stoke) , hepatic diseases, cancer, HIV, Hepatitis C Virus (HCV), and unstable psychiatric comorbidities.

For healthy controls

  • Participant under guardianship or under justice safeguard measures
  • Participant under measure of therapeutic injunction
  • Pregnancy or breastfeeding declared
  • Meeting DSM-5 criteria for alcohol use disorder
  • Meeting DSM-5 criteria for substance use disorder other than Tobacco
  • Meeting DSM-5 criteria for non substance use disorder
  • Currently under benzodiazepine
  • Participant presenting severe or progressive disease that interfere with experimental tasks, such as neurological diseases (TBI, epilepsy, stoke) , hepatic diseases, cancer, HIV, HCV, and unstable psychiatric comorbidities.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
41 participants (actual)
Patient registry
No

Groups and cohorts

  • Alcohol use disorder patients
  • Healthy controls
06

What researchers measure

Primary outcomes

  1. Description of the semantic associations using FGAT

    The Free Generation Associated Tasks will be used in Alcohol use disorder patients and Healthy controls

    Time frame: At baseline (T1)

  2. Description of the semantic associations using AJT

    The Associative Judgment Task will be used in Alcohol use disorder patients and Healthy controls

    Time frame: At baseline (T1)

Secondary outcomes

  1. Impact of medications on the semantic association performance

    Time frame: At baseline (T1)

  2. Impact of age on the semantic association performance

    Time frame: At baseline (T1)

  3. Impact of the study level on the semantic association performance

    Time frame: At baseline (T1)

  4. Impact of gender on the semantic association performance

    Time frame: At baseline (T1)

  5. Impact of the duration of dependence on the semantic association performance

    Time frame: At baseline (T1)

  6. Impact of cognitive performance on the semantic association performance

    The Go /No Go performance will be collected in Alcohol use disorder patients

    Time frame: At baseline (T1)

  7. Test of the predictive value of FGAT performance assessed at T1 on alcohol consumption during the six weeks following the Baseline

    Time frame: Baseline (T1) for FGAT ; T2 (6 weeks after T1) for alcohol consumption

  8. Test of the predictive value of AJT performance assessed at T1 on alcohol consumption during the six weeks following the Baseline

    Time frame: Baseline (T1) for AJT ; T2 (6 weeks after T1) for alcohol consumption

  9. Test of the predictive value of FGAT performance assessed at T1 on alcohol consumption during the three months following the Baseline

    Time frame: Baseline (T1) for FGAT ; T3 (3 months after T1) for alcohol consumption

  10. Test of the predictive value of AJT performance assessed at T1 on alcohol consumption during the three months following the Baseline

    Time frame: Baseline (T1) for AJT ; T3 (3 months after T1) for alcohol consumption

  11. Evolution of FGAT performance, comparison between alcohol use disorder patients and healthy controls

    Time frame: T1 (baseline) and T3 (3 months after baseline)

  12. Evolution of AJT performance, comparison between alcohol use disorder patients and healthy controls

    Time frame: T1 (baseline) and T3 (3 months after baseline)

  13. Link between the evolution of FGAT performance and the level of alcohol consumption

    The level of alcohol consumption will be assessed using the Timeline Followback method

    Time frame: Baseline (T1) for FGAT and 3 months after baseline (T3) for FGAT and the level of alcohol consumption)

  14. Link between the evolution of AJT performance and alcohol consumption

    The level of alcohol consumption will be assessed using the Timeline Followback method

    Time frame: Baseline (T1) for AJT and 3 months after baseline (T3) for AJT and the level of alcohol consumption)

  15. Link between the evolution of FGAT performance and the evolution of cognitive performance

    The Go /No Go performance will be used in alcohol use disorder patients

    Time frame: Baseline (T1) and 3 months after baseline (T3)

  16. Link between the evolution of AJT performance and the evolution of cognitive performance

    The Go /No Go performance will be used in alcohol use disorder patients

    Time frame: Baseline (T1) and 3 months after baseline (T3)

07

Study locations

1 site
  • Fernand Widal Hospital
    Paris, Île-de-France Region 75010, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05636033
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Dec 5, 2022
Start date
Apr 19, 2023
Primary completion
Oct 7, 2025
Completion
Oct 7, 2025
Last update
Apr 27, 2026

Study contacts

Alexandra Dereux, PH (MD)
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion